Repros Therapeutics is a development-stage biopharmaceutical company focused on developing oral small molecule drugs to address major unmet medical needs for male and female reproductive disorders. The company’s primary product candidate is Androxal, an orally active proprietary small molecule compound being developed for men of reproductive age with low testosterone levels.  The company is also studying Proellex as a treatment for uterine fibroids in women. For more information, visit the company’s Web site at www.reprosrx.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: